Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

ReportsWorldwide has announced the addition of a new report title
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline to its growing collection of premium market research reports.

Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.

Scope of the Report:

The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries.

The market is mostly dominated by generics, and there are only a few patented products.

- Will generics continue to dominate treatment?

- How do the elderly populations and their associated risk factors affect prevalence?

- What effect will the patent expirations of currently branded therapies have on market value?

The current anti-hypertensive therapeutics pipeline is weak, comprising 112 molecules in various stages of development, dominated by small molecules.

- Which molecular targets appear most frequently in the pipeline?

- Is there potential for the pipeline to address unmet needs within the anti-hypertensive market?

Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?

- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the high annual cost of therapy. Growth in market size is projected to vary considerably across the five assessed markets.

- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?

- How could changes in risk factors such as aging population, metabolic disorders and high salt intake influence the market?

- Various drivers and barriers will influence the market over the forecast period.

- What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?

- Which factors are most likely to drive the market in these countries?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6857

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

- Visualize the composition of the anti-hypertensive market in terms of the dominant therapies, and their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

- Analyze the anti-hypertensive pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

- Consider market opportunities and potential risks by examining trends in hypertension clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.

- Predict anti-hypertensive market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

- Identify commercial opportunities in the anti-hypertensive deals landscape by analyzing trends in licensing and co-development deals.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/anti-hypertensive-therapeutics-in-asia-pacific-markets-to-2022-increasing-prevalence-of-hypertension-drives-market-growth-despite-weak-pipeline

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.